Evidence map›Paper›PMID 28598362›Full record

ReviewCancers2017

Carbon Ion Radiotherapy: A Review of Clinical Experiences and Preclinical Research, with an Emphasis on DNA Damage/Repair.

Osama Mohamad, Brock J Sishc, Janapriya Saha, Arnold Pompos, Asal Rahimi, Michael D Story, Anthony J Davis, D W Nathan Kim

Abstract readReview
In one paragraph

Review in Cancers, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
97citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

97 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

37 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Osama MohamadDepartment of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Osama.mohamad@utsouthwestern.edu.
Brock J SishcDepartment of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Brock.Sishc@utsouthwestern.edu.
Janapriya SahaDepartment of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Janapriya.Saha@utsouthwestern.edu.
Arnold PomposDepartment of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Arnold.Pompos@utsouthwestern.edu.
Asal RahimiDepartment of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Asal.Rahimi@utsouthwestern.edu.
Michael D StoryDepartment of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Michael.Story@utsouthwestern.edu.
Anthony J DavisDepartment of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Anthony.Davis@utsouthwestern.edu.
D W Nathan KimDepartment of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Nathan.Kim@utsouthwestern.edu.

Funding

National Particle Therapy Research Center (NPTRC)P20CA183639 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI JIANG, STEVE BIN · 2015 to 2016
$1.0M
NCI NIH HHS P20 CA183639
6 · The paper itself

Abstract

Compared to conventional photon-based external beam radiation (PhXRT), carbon ion radiotherapy (CIRT) has superior dose distribution, higher linear energy transfer (LET), and a higher relative biological effectiveness (RBE). This enhanced RBE is driven by a unique DNA damage signature characterized by clustered lesions that overwhelm the DNA repair capacity of malignant cells. These physical and radiobiological characteristics imbue heavy ions with potent tumoricidal capacity, while having the potential for simultaneously maximally sparing normal tissues. Thus, CIRT could potentially be used to treat some of the most difficult to treat tumors, including those that are hypoxic, radio-resistant, or deep-seated. Clinical data, mostly from Japan and Germany, are promising, with favorable oncologic outcomes and acceptable toxicity. In this manuscript, we review the physical and biological rationales for CIRT, with an emphasis on DNA damage and repair, as well as providing a comprehensive overview of the translational and clinical data using CIRT.

Indexed as

carbon therapycomplex DNA damageDNA repairhadron therapyproton therapyradiation oncology

Identifiers

PMID28598362
PMCPMC5483885

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.